Comparative Pharmacology
Head-to-head clinical analysis: DURADYNE DHC versus NUMORPHAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURADYNE DHC versus NUMORPHAN.
DURADYNE DHC vs NUMORPHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DURADYNE DHC contains dihydrocodeine, an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception and response.
Opioid agonist; binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception.
1 tablet (10 mg hydrocodone/300 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Intravenous or subcutaneous: 0.5-2 mg (0.1-0.2 mg/kg for severe pain) every 2-3 hours as needed; not to exceed 20 mg/day.
None Documented
None Documented
Terminal elimination half-life of dihydrocodeine is approximately 4 hours; clinically relevant for dosing interval of 4-6 hours.
Terminal elimination half-life is 2–3 hours in adults; prolonged to 3–4 hours in elderly and up to 15 hours in patients with severe hepatic impairment.
Primarily renal excretion of metabolites; ~90% excreted in urine as glucuronide conjugates and morphine; ~10% in feces via bile.
Primarily renal (approximately 70% as unchanged drug, <5% as noroxymorphone and other conjugates); biliary/fecal excretion accounts for ~20%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic